🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In our new paper #JACCHF, led by Colette DeJong, ARNI and SGLT2i marketing to cardiologists was associated with their greater use. The association was specific to the drug marketed, and did not extend to other GDMT pillars. JACC Journals Dhruv Kazi jacc.org/doi/full/10.10…

Our paper on the effect of herpes zoster vaccination on dementia is now out in Nature! 🎉 Huge thanks to Felix Michalik, Seunghun Chung, Pascal Geldsetzer, and especially Min Xie (Min Xie) & Simon Heß(simon heß) for making the analysis so much fun! 🔗 nature.com/articles/s4158…

Loved working w these brilliant economists on this NEJM Evidence paper - a primer on applying instrumental variables to RCTs when adherence to treatment arm is imperfect. Applied to the ISCHEMIA trial, we find that the effects of revasc on angina were greater than most think.

Honored to receive the Young Scientist Award 2025 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan!

📢 Our study published in Nature Medicine is now featured in a short video! We evaluated a smartphone CBT app (“Resi-Tre”) in a large-scale RCT (n=3,936) 📊 Which skills work best for depression, insomnia, anxiety? 🎥 Watch here: youtube.com/watch?v=m5jcQS…

Our newest viewpoint paper is out in JAMA Psychiatry! JAMA Psychiatry We outline 3 key considerations for mediation analysis in psychiatric research: 1. Temporal plausibility 2. Confounding (not only exposure-outcome confounding) 3. Exposure-mediator interaction

Thank you so much for the opportunity to share my work at CAUSALab ! I really enjoyed the discussion—so many important questions remain to be explored! 京都大学白眉センター Kyoto University Hakubi Center 京都大学 @harvardchan BIDMC Smith Center

In our new JAMA Internal Medicine study, depressive symptoms among US adults worsened in 2021-2023, particularly among young adults (20-44 yrs). jamanetwork.com/journals/jamai… Collaboration w/ @LiuMichaelON Rishi Wadhera, MD MPP Rahul Aggarwal Lucas Marinacci, MD & Dr. Koh. BIDMC Smith Center Kyoto University

The prevalence of depressive symptoms among US adults increased during the COVID-19 pandemic, with the most notable rise observed in younger adults. ja.ma/3GMUuih Rishi Wadhera, MD MPP Kosuke Inoue

Our new JAMA Internal Medicine study finds a sharp ⬆️ depressive symptoms among US adults during the pandemic Worsening mental health was concentrated in young adults, who may have disproportionately been impacted by societal disruptions jamanetwork.com/journals/jamai…

The proposed “Most Favored Nation Drug Pricing” (MFN-DP) plan is the most ambitious plan yet to rein in US drug spending. How did we get here? How would MFN-DP work? What are the expected short, intermediate, & long-term consequences? Here are my top 10 takeaways (so far)- 1/

What happens when low-income Medicare beneficiaries lose subsidized drug coverage (aka the Part D Low Income Subsidy)? Unfortunately, they are much more likely to die. And these deaths are likely preventable . Our new NEJM study out today nejm.org/doi/full/10.10…

New paper published at AJE Advances: "The role of estimation in Mendelian randomization: should Mendelian randomization investigations provide estimates?" led by Benji Woolf and myself. Brief thread:

Without its international students, Harvard is not Harvard. hrvd.me/IntStudents25t

Our new paper in AEA P&P AEA Journals, led by Susan Athey, explains why distinguishing conditional ITT, compliance (adherence) CATE, and CLATE matters for targeted treatment strategy. Collab with Yusuke Tsugawa 京都大学 京都大学白眉センター Kyoto University Hakubi Center UCLA Fielding School of Public Health 🔗 aeaweb.org/articles?id=10…

📢 Our new study in JAMA Health Forum: We investigated 10 types of low-value care (LVC) in primary care. 1~ in 10 patients received at least one LVC per year, mostly from a small group of physicians. 🔗 doi.org/10.1001/jamahe… 津川 友介 阿部計大/Kazuhiro Abe John Mafi

No heterogeneity in excellence in presentations on heterogeneous treatment effects 💊by Kosuke Inoue Kosuke Inoue (visiting scientist CAUSALab Kyoto University) and Sarah Robertson Sarah Robertson (research collaborator CAUSALab Geisel School of Medicine at Dartmouth) Chaired by Issa Dahabreh #SER2025 Am J Epidemiology

京都大学白眉プロジェクト創始者・松本紘元総長のご逝去に際し、深く哀悼の意を表します。 研究者が自由に学び合い、成長できる場を生み出してくださったそのご功績に、心から感謝申し上げます。 hakubi.kyoto-u.ac.jp/news/20250615_…

Our new paper about trends in childhood obesity in the US 2011-2023 is now published in Annals of Int Med! Congratulations Michael Liu, MD, MPhil and team!

Presented at #ENDO2025: In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia. Full SPARK study results: